Announcement • Jun 06
Medpace Holdings, Inc. Announces Appointment of Brad W. Hansman to Executive Vice President, Operations, Effective June 1, 2026 Effective June 1, 2026, Medpace Holdings, Inc. appointed Brad W. Hansman, age 43, to the position of Executive Vice President, Operations. In this role, Mr. Hansman shall perform the functions of the Company’s principal operating officer along with Susan E. Burwig, the Company’s Executive Vice President, Operations. Mr. Hansman joined the Company in April 2011 in Finance & Accounting and held various roles in Finance until July 2015. Since August 2015, Mr. Hansman has held various key leadership roles in operations including Executive Director, Vice President, and Senior Vice President overseeing study start-up, logistics, regulatory affairs, and medical writing. Prior to joining the Company, Mr. Hansman worked for Joseph Decosimo & Company, LLC as an Audit Supervisor from July 2008 to March 2011. Mr. Hansman started his career at Macy’s, Inc. where he held various auditor positions from July 2006 to June 2008. Mr. Hansman received his Bachelor of Business Administration in Accounting from Eastern Kentucky University and is a Certified Public Accountant (inactive). Mr. Hansman does not hold any public company directorships. Board Change • Apr 30
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 3 highly experienced directors. Independent Director Dani Zander was the last director to join the board, commencing their role in 2024. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Announcement • Apr 23
Medpace Holdings, Inc. Provides Earnings Guidance for the Year 2026 Medpace Holdings, Inc. provided earnings guidance for the year 2026. For the year, the company forecasts revenue in the range of $2.755 billion to $2.855 billion, representing growth of 8.9% to 12.8% over 2025 revenue of $2.530 billion. GAAP net income for full year 2026 is forecasted in the range of $487.0 million to $511.0 million. Based on forecasted 2026 revenue of $2.755 billion to $2.855 billion and GAAP net income of $487.0 million to $511.0 million, diluted earnings per share (GAAP) is forecasted in the range of $16.68 to $17.50. This guidance assumes a full year 2026 tax rate of 19.0% to 20.0%, interest income of $27.5 million, foreign exchange rates as of March 31, 2026, and 29.2 million diluted weighted average shares outstanding. Buy Or Sell Opportunity • Mar 27
Now 22% undervalued after recent price drop Over the last 90 days, the stock has fallen 23% to €385. The fair value is estimated to be €496, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Earnings per share has grown by 24%. For the next 3 years, revenue is forecast to grow by 8.5% per annum. Earnings are also forecast to grow by 9.5% per annum over the same time period. Announcement • Mar 25
Medpace Holdings, Inc. to Report Q1, 2026 Results on Apr 22, 2026 Medpace Holdings, Inc. announced that they will report Q1, 2026 results After-Market on Apr 22, 2026 Announcement • Mar 17
Medpace Holdings, Inc., Annual General Meeting, May 15, 2026 Medpace Holdings, Inc., Annual General Meeting, May 15, 2026. Buy Or Sell Opportunity • Mar 12
Now 24% undervalued after recent price drop Over the last 90 days, the stock has fallen 20% to €376. The fair value is estimated to be €493, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Earnings per share has grown by 24%. For the next 3 years, revenue is forecast to grow by 8.5% per annum. Earnings are also forecast to grow by 9.5% per annum over the same time period. Buy Or Sell Opportunity • Feb 12
Now 28% undervalued after recent price drop Over the last 90 days, the stock has fallen 37% to €328. The fair value is estimated to be €453, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Earnings per share has grown by 24%. For the next 3 years, revenue is forecast to grow by 8.7% per annum. Earnings are also forecast to grow by 9.4% per annum over the same time period. Board Change • Feb 12
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 3 highly experienced directors. Independent Director Dani Zander was the last director to join the board, commencing their role in 2024. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Announcement • Feb 10
Medpace Holdings, Inc. Provides Earnings Guidance for the Full Year of 2026 Medpace Holdings, Inc. provides earnings guidance for the full year of 2026. For the period, the company expects revenue in the range of $2.755 billion to $2.855 billion, representing growth of 8.9% to 12.8% over 2025 revenue of $2.530 billion. GAAP net income is forecasted in the range of $487.0 million to $511.0 million, diluted earnings per share (GAAP) is forecasted in the range of $16.68 to $17.50. Board Change • Feb 01
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 3 highly experienced directors. Independent Director Dani Zander was the last director to join the board, commencing their role in 2024. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Buy Or Sell Opportunity • Jan 24
Now 21% undervalued after recent price drop Over the last 90 days, the stock has fallen 7.5% to €473. The fair value is estimated to be €598, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Earnings per share has grown by 25%. For the next 3 years, revenue is forecast to grow by 10% per annum. Earnings are also forecast to grow by 10% per annum over the same time period. Announcement • Jan 06
Medpace Holdings, Inc. to Report Q4, 2025 Results on Feb 09, 2026 Medpace Holdings, Inc. announced that they will report Q4, 2025 results After-Market on Feb 09, 2026 New Risk • Nov 24
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Italian stocks, typically moving 5.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (5.8% average weekly change). Significant insider selling over the past 3 months (€62m sold). Recent Insider Transactions • Nov 13
Executive Vice President of Operations recently sold €9.4m worth of stock On the 11th of November, Susan Burwig sold around 18k shares on-market at roughly €522 per share. This transaction amounted to 27% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth €15m. Susan has been a net seller over the last 12 months, reducing personal holdings by €17m. Recent Insider Transactions • Oct 30
Executive Vice President of Operations recently sold €1.0m worth of stock On the 27th of October, Susan Burwig sold around 2k shares on-market at roughly €520 per share. This transaction amounted to 3.0% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth €15m. Susan has been a net seller over the last 12 months, reducing personal holdings by €8.1m. Reported Earnings • Oct 23
Third quarter 2025 earnings released: EPS: US$3.95 (vs US$3.11 in 3Q 2024) Third quarter 2025 results: EPS: US$3.95 (up from US$3.11 in 3Q 2024). Revenue: US$659.9m (up 24% from 3Q 2024). Net income: US$111.1m (up 15% from 3Q 2024). Profit margin: 17% (down from 18% in 3Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 9.4% p.a. on average during the next 3 years, compared to a 9.5% growth forecast for the Life Sciences industry in Europe. Announcement • Oct 23
Medpace Holdings, Inc. Provides Earnings Guidance for the Full Year 2025 Medpace Holdings, Inc. provided earnings guidance for the full year 2025. The Company forecasts 2025 revenue in the range of $2.480 billion to $2.530 billion, representing growth of 17.6% to 20.0% over 2024 revenue of $2.109 billion. GAAP net income for full year 2025 is forecasted in the range of $431.0 million to $439.0 million. Diluted earnings per share (GAAP) is forecasted in the range of $14.60 to $14.86. Buy Or Sell Opportunity • Oct 10
Now 20% undervalued Over the last 90 days, the stock has risen 59% to €436. The fair value is estimated to be €547, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 18% over the last 3 years. Earnings per share has grown by 27%. For the next 3 years, revenue is forecast to grow by 9.7% per annum. Earnings are also forecast to grow by 8.1% per annum over the same time period. Announcement • Sep 24
Medpace Holdings, Inc. to Report Q3, 2025 Results on Oct 22, 2025 Medpace Holdings, Inc. announced that they will report Q3, 2025 results After-Market on Oct 22, 2025 Recent Insider Transactions • Sep 04
Chairman & CEO recently sold €15m worth of stock On the 2nd of September, August Troendle sold around 37k shares on-market at roughly €408 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth €19m. August has been a net seller over the last 12 months, reducing personal holdings by €34m. Recent Insider Transactions • Aug 22
Independent Director recently sold €662k worth of stock On the 19th of August, Cornelius McCarthy sold around 2k shares on-market at roughly €398 per share. This transaction amounted to 14% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth €19m. Insiders have been net sellers, collectively disposing of €24m more than they bought in the last 12 months. Recent Insider Transactions • Jul 30
Chairman & CEO recently sold €19m worth of stock On the 28th of July, August Troendle sold around 48k shares on-market at roughly €389 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was August's only on-market trade for the last 12 months. Reported Earnings • Jul 23
Second quarter 2025 earnings released: EPS: US$3.16 (vs US$2.85 in 2Q 2024) Second quarter 2025 results: EPS: US$3.16 (up from US$2.85 in 2Q 2024). Revenue: US$603.3m (up 14% from 2Q 2024). Net income: US$90.3m (up 2.2% from 2Q 2024). Profit margin: 15% (down from 17% in 2Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 9.7% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Life Sciences industry in Europe. Announcement • Jul 22
Medpace Holdings, Inc. Updates Earnings Guidance for the Full Year 2025 Medpace Holdings, Inc. updated earnings guidance for the full year 2025. For the year company expects revenue in the range of $2.420 billion to $2.520 billion, representing growth of 14.7% to 19.5% over 2024 revenue of $2.109 billion. GAAP net income for full year 2025 is forecasted in the range of $405.0 million to $428.0 million. Based on forecasted 2025 revenue of $2.420 billion to $2.520 billion and GAAP net income of $405.0 million to $428.0 million, diluted earnings per share (GAAP) is forecasted in the range of $13.76 to $14.53. Announcement • Jun 24
Medpace Holdings, Inc. to Report Q2, 2025 Results on Jul 21, 2025 Medpace Holdings, Inc. announced that they will report Q2, 2025 results After-Market on Jul 21, 2025